Abstract
The effect of the free radical scavenger edaravone on experimental cerebral vasospasm
following subarachnoid hemorrhage (SAH) was investigated in a canine double hemorrhage
model. Changes in the diameter of the basilar artery were assessed by serial angiography.
The diameter ratio at day 7 was calculated as the percent of the basilar artery diameter
of a given angiogram with respect to that of its control (day 0). The diameter ratios
for the basilar artery following SAH in the control and vehicle-treated groups were
49.7% ± 3.9% (mean ± SEM) and 50.1% ± 1.7%, respectively. Edaravone was administered
either by continuous intravenous injection for 7 days or by bolus injection for 7
days. Continuous administration of edaravone (1 mg/kg/hr or 10 mg/kg/hr) significantly
attenuated the narrowing of the basilar artery following SAH. The diameter ratios
in these groups were 71.3% ± 3.6% (1 mg/kg/hr) and 75.7% ± 1.7% (10 mg/kg/hr). Bolus
administration of edaravone (3 mg/kg, every 12 hours) reduced the arterial narrowing
following SAH. The diameter ratio on day 7 was 60.1% ± 3.3%, but the difference was
not significant. These findings suggest that edaravone is effective in preventing
cerebral vasospasm following SAH. Copyright © 2003 by National Stroke Association
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Stroke and Cerebrovascular DiseasesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A review of cerebral vasospasm in aneurysmal subarachnoid hemorrhage.J Clin Neurosci. 1994; 1: 19-26
- Iron promoters of the Fenton reaction and lipid peroxidation can be released from hemoglobin by peroxides.FEBS Lett. 1986; 201: 291-295
- Liposome oxidation and erythrocyte lysis by enzymically generated superoxide and hydrogen peroxide.J Biol Chem. 1977; 252: 6721-6728
- Reactions involving superoxide and normal and unstable haemoglobin.Biochem J. 1976; 155: 493-502
- Experimental evaluation of the beneficial effect of an antioxidant on cerebral vasospasm.Neurol Res. 1984; 6: 49-53
- Effects of a hydroxy radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial.J Neurosurg. 1996; 84: 792-803
- Experimental vasospasm, acute and chronic, due to blood in the subarachnoid space.J Neurosurg. 1971; 35: 646-656
- Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning.Neurosurgery. 1980; 6: 1-9
- A review of hemoglobin and the pathogenesis of cerebral vasospasm.Stroke. 1991; 22: 971-982
- The role of hemoglobin in arterial narrowing after subarachnoid hemorrhage.J Neurosurg. 1990; 72: 634-640
- Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage.Neurosurgery. 1998; 42: 269-277
- Cerebral vasospasm: contractile activity of hemoglobin in isolated canine basilar arteries.J Neurosurg. 1980; 53: 787-793
- The control of vascular endothelial injury.Ann NY Acad Sci. 1990; 598: 182-187
- Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro.Prostaglandins Leukot Essent Fatty Acids. 1988; 33: 81-87
- Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions.J Pharmacol Exp Ther. 1994; 268: 1597-1604
- Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger.Stroke. 1988; 19: 480-485
- Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.J Pharmacol Exp Ther. 1997; 281: 921-927
- Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion.Gen Pharmacol. 1998; 30: 575-578
- Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension.Neurosurgery. 1982; 11: 337-343
- Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution (triple-H therapy) after subarachnoid hemorrhage.Neurosurgery. 1990; 27: 729-739
- Calcium antagonists for aneurysmal subarachnoid hemorrhage.Cochrane Database of Systemic Reviews. 2000; ([Cochrane Review]) (Oxford: Update Software)
- Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage.J Neurosurg. 1988; 68: 393-400
- Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysmal nimodipine trial.Br Med J. 1989; 298: 636-642
- Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: results of a prospective placebo-controlled double-blind trial.J Neurosurg. 1992; 74: 571-577
- A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.Neurosurgery. 1995; 37: 168-178
- Cisternal irrigation therapy with urokinase and ascorbic acid for prevention of vasospasm after aneurysmal subarachnoid hemorrhage.Surg Neurol. 2000; 53: 110-118
- Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue type plasminogen activator.J Neurosurg. 1993; 78: 430-437
- Cisternal washing therapy for the prevention of cerebral vasospasm following aneurysmal subarachnoid hemorrhage.Acta Neurochir. 2001; 77: 161-165
- Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage.J Neurosurg. 1991; 75: 197-201
- A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage.Neurosurgery. 1994; 35: 597-605
- Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with subarachnoid hemorrhage.J Neurosurg. 1991; 75: 189-196
- Observations on the perioperative management of aneurysmal subarachnoid hemorrhage.J Neurosurg. 1986; 65: 48-62
- Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage.J Neurosurg. 1989; 71: 98-104
- Ebselen (DR3305) ameliorates delayed cerebral vasospasm in a canine two-hemorrhage model.Neurol Res. 1997; 19: 563-565
- Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand.J Neurosurg. 1996; 84: 221-228
Article info
Publication history
Accepted:
October 19,
2002
Received in revised form:
October 15,
2002
Received:
August 2,
2002
Footnotes
*Address reprint requests to: Tadayoshi Nakagomi, MD, Department of Neurosurgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.
Identification
Copyright
© 2003 National Stroke Association. Published by Elsevier Inc. All rights reserved.
